Advanced search
Publication Cover
Acta Orthopaedica Volume 87, 2016 - Issue 4
Journal homepage
1,292
Views
27
CrossRef citations to date
0
Altmetric
Original Articles

Increased bone formation in a rabbit long-bone defect model after single local and single systemic application of erythropoietin

Georg W OmlorCenter for Orthopedics, Trauma Surgery and Spinal Cord Injury, Heidelberg University Hospital;
,
Kerstin KleinschmidtResearch Center for Experimental Orthopedics, Heidelberg University Hospital;
,
Simone GantzCenter for Orthopedics, Trauma Surgery and Spinal Cord Injury, Heidelberg University Hospital;
,
Anja SpeicherResearch Center for Experimental Orthopedics, Heidelberg University Hospital;
,
Thorsten GuehringBG Trauma Hospital Ludwigshafen, University of Heidelberg, Germany
&
Wiltrud RichterResearch Center for Experimental Orthopedics, Heidelberg University Hospital; Correspondence[email protected]
Pages 425-431 | Received 09 Nov 2015, Accepted 07 Apr 2016, Published online: 27 Jun 2016

  • Anagnostou A, Lee ES, Kessimian N, Levinson R, Steiner M. Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc Natl Acad Sci U S A 1990; 87(15): 5978–82.
  • Arcasoy M O. Non-erythroid effects of erythropoietin. Haematologica 2010; 95(11): 1803–5.
  • Bozlar M, Kalaci A, Aslan B, Baktiroglu L, Yanat A N, Tasci A. Effects of erythropoietin on fracture healing in rats. Saudi Medical Journal 2006; 27(8): 1267–9.
  • Bohr S, Patel S J, Shen K, Vitalo A G, Brines M, Cerami A, Berthiaume F, Yarmush M L. Alternative erythropoietin-mediated signaling prevents secondary microvascular throm-bosis and inflammation within cutaneous burns. Proc Natl Acad Sci U S A 2013; 110(9): 3513–8.
  • Brines M, Cerami A. Erythropoietin-mediated tissue protection: reducing collateral damage from the primary injury response. J Intern Med 2008; 264(5): 405–32.
  • Brines M, Grasso G, Fiordaliso F, Sfacteria A, Ghezzi P, Fratelli M, Latini R, Xie Q W, Smart J, Su-Rick C J, Pobre E, Diaz D, Gomez D, Hand C, Coleman T, Cerami A. Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc Natl Acad Sci USA 2004; 101(41): 14907–12.
  • Chateauvieux S, Grigorakaki C, Morceau F, Dicato M, Diederich M. Erythropoietin, erythropoiesis and beyond. Biochem Pharmacol 2011; 82(10):1291–303.
  • Garcia P, Speidel V, Scheuer C, Laschke M W, Holstein J H, Histing T, Pohlemann T, Menger M D. Low dose erythropoietin stimulates bone healing in mice. J Orthop Res 2011; 29(2): 165–72.
  • Geiger F, Bertram H, Berger I, Lorenz H, Wall O, Eckhardt C, Simank H G, Richter W. Vascular endothelial growth factor gene-activated matrix (VEGF165-GAM) enhances osteogenesis and angiogenesis in large segmental bone defects. J Bone Miner Res 2005; 20(11): 2028–35.
  • Geiger F, Lorenz H, Xu W, Szalay K, Kasten P, Claes L, Augat P, Richter W. VEGF producing bone marrow stromal cells (BMSC) enhance vascularization and resorption of a natural coral bone substitute. Bone 2007; 41(4): 516–22.
  • Goncalves S, Chiossone-Kerdel JA, Bianco AS, Ercolino J M, Hernandez-Rojas J. Effect of absorbable gelatin sponge in the middle ear: in vitro and in vivo animal model. Acta Otolaryngol 2015; 135(1): 14–25.
  • Heeschen C, Aicher A, Lehmann R, Fichtlscherer S, Vasa M, Urbich C, Mildner-Rihm C, Martin H, Zeiher A M, Dimmeler S. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood 2003; 102(4): 1340–6.
  • Henry D H. Epoetin alfa for the treatment of cancer- and chemotherapy-related anaemia: product review and update. Expert Opin Pharmacother 2005; 6(2): 295–310.
  • Hiram-Bab S, Liron T, Deshet-Unger N, Mittelman M, Gassmann M, Rauner M, Franke K, Wielockx B, Neumann D, Gabet Y. Erythropoietin directly stimulates osteoclast precursors and induces bone loss. FASEB J 2015; 29(5): 1890–900.
  • Holstein J H, Menger M D, Scheuer C, Meier C, Culemann U, Wirbel R J, Garcia P, Pohlemann T. Erythropoietin (EPO): EPO-receptor signaling improves early endochondral ossification and mechanical strength in fracture healing. Life Sci 2007; 80(10): 893–900.
  • Holstein J H, Orth M, Scheuer C, Tami A, Becker S C, Garcia P, Histing T, Mörsdorf P, Klein M, Pohlemann T, Menger M D. Erythropoietin stimulates bone formation, cell proliferation, and angiogenesis in a femoral segmental defect model in mice. Bone 2011; 49(5): 1037–45.
  • Jaquet K, Krause K, Tawakol-Khodai M, Geidel S, Kuck K-H. Erythropoietin and VEGF exhibit equal angiogenic potential. Microvasc Res 2002; 64(2): 326–33.
  • Jelkmann W. Erythropoietin: structure, control of production, and function. Physiol Rev 1992; 72(2): 449–89.
  • Kleinschmidt K, Ploeger F, Nickel J, Glockenmeier J, Kunz P, Richter W. Enhanced reconstruction of long bone architecture by a growth factor mutant combining positive features of GDF-5 and BMP-2. Biomaterials 2013; 34(24): 5926–36.
  • Kleinschmidt K, Wagner-Ecker M, Bartek B, Holschbach J, Richter W. Superior angiogenic potential of GDF-5 and GDF-5(V453/V456) compared with BMP-2 in a rabbit long-bone defect model. J Bone Joint Surg Am 2014; 96(20):
  • Leist M, Ghezzi P, Grasso G, Bianchi R, Villa P, Fratelli M, Savino C, Bianchi M, Nielsen J, Gerwien J, Kallunki P, Larsen A K, Helboe L, Christensen S, Pedersen L O, Nielsen M, Torup L, Sager T, Sfacteria A, Erbayraktar S, Erbayraktar Z, Gokmen N, Yilmaz O, Cerami-Hand C, Xie Q W, Coleman T, Cerami A, Brines M. Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 2004; 305(5681): 239–42.
  • McGee SJ, Havens AM, Shiozawa Y, Jung Y, Taichman RS. Effects of erythropoietin on the bone microenvironment. Growth Factors 2012; 30(1): 22–8.
  • Prunier F, Pfister O, Hadri L, Liang L, Del Monte F, Liao R, Hajjar RJ. Delayed erythropoietin therapy reduces post-MI cardiac remodeling only at a dose that mobilizes endothelial progenitor cells. Am J Physiol Heart Circ Physiol 2007; 292(1): H522–9.
  • Rölfing J H D. The effect of erythropoietin on bone. Acta Orthop 2014; 85 (Suppl 353):1–27.
  • Rölfing J H D, Bendtsen M, Jensen J, Stiehler M, Foldager CB, Hellfritzsch M B, Bünger C. Erythropoietin augments bone formation in a rabbit posterolateral spinal fusion model. J Orthop Res 2012; 30(7): 1083–8.
  • Rölfing J H D, Jensen J, Jensen J N, Greve A-S, Lysdahl H, Chen M, Rejnmark L, Bünger C. A single topical dose of erythropoietin applied on a collagen carrier enhances calvarial bone healing in pigs. Acta Orthop 2014a; 85(2): 201–9.
  • Rölfing J H D, Baatrup A, Stiehler M, Jensen J, Lysdahl H, Bünger C. The osteogenic effect of erythropoietin on human mesenchymal stromal cells is dose-dependent and involves non-hematopoietic receptors and multiple intracellular signaling pathways. Stem Cell Rev 2014b; 10(1): 69–78.
  • Shiozawa Y, Jung Y, Ziegler AM, Pedersen EA, Wang J, Wang Z, Song J, Wang J, Lee CH, Sud S, Pienta KJ, Krebsbach PH, Taichman RS. Erythropoietin couples hematopoiesis with bone formation. PLoS ONE 2010; 5(5): e10853.
  • Sun H, Jung Y, Shiozawa Y, Taichman R S, Krebsbach P H. Erythropoietin modulates the structure of bone morphogenetic protein 2-engineered cranial bone. Tissue Eng Part A 2012; 18(19-20): 2095–105.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.